Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 5/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.46 |
| ▸ | TLR5 | O60602 | 3/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7991495 | 0.81 | PIK3CA (0.45) | PRKCIPIK3CALIMK1CLK1CDC7 | |
| SCHEMBL16194826 | 0.77 | PRKCI (0.64) | PRKCIPIK3CALIMK1TLR5CLK1 | |
| SCHEMBL16195089 | 0.77 | PRKCI (0.62) | PRKCIPIK3CALIMK1TLR5CLK1 | |
| SCHEMBL14986511 | 0.76 | PRKCI (1.00) | PRKCI | |
| SCHEMBL14986509 | 0.76 | PRKCI (1.00) | PRKCIPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL23378544 | 0.74 | PIK3CA (0.59) | PRKCIPIK3CALIMK1CLK1CDC7 | |
| SCHEMBL14986512 | 0.74 | PRKCI (1.00) | PRKCI | |
| SCHEMBL14986499 | 0.74 | PRKCI (1.00) | PRKCI | |
| SCHEMBL14986502 | 0.73 | PRKCI (1.00) | PRKCIPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL15645174 | 0.72 | ABCG2 (0.48) | PIK3CAPIK3CDPIK3CGKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| EP-3048106-B1 | THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2019-11-06 | — | — | EP | disclosed |
| EP-3048106-B1 | THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2019-11-06 | — | — | EP | disclosed |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | WINDTREE THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | WINDTREE THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-22 | — | — | US | disclosed |
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-22 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| EP-2782917-B1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER REC TECH LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| EP-2782917-B1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER REC TECH LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-2782990-A1 | METHODS AND SYSTEMS FOR GROWING PLANTS USING SILICATE-BASED SUBSTRATES, CULTIVATION OF ENHANCED PHOTOSYNTHETIC PRODUCTIVITY AND PHOTOSAFENING BY UTILIZATION OF EXOGENOUS GLYCOPYRANOSIDES FOR ENDOGENOUS GLYCOPYRANOSYL-PROTEIN DERIVATIVES, AND FORMULATIONS, PROCESSES AND SYSTEMS FOR THE SAME | Nonomura, Arthur M. (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2782917-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2014-10-01 | — | — | EP | disclosed |
| WO-2013078126-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078106-A1 | METHODS AND SYSTEMS FOR GROWING PLANTS USING SILICATE-BASED SUBSTRATES, CULTIVATION OF ENHANCED PHOTOSYNTHETIC PRODUCTIVITY AND PHOTOSAFENING BY UTILIZATION OF EXOGENOUS GLYCOPYRANOSIDES FOR ENDOGENOUS GLYCOPYRANOSYL-PROTEIN DERIVATIVES, AND FORMULATIONS, PROCESSES AND SYSTEMS FOR THE SAME | NONOMURA ARTHUR M (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078126-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183950-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKCQ, PRKDC, PRKACA | PRKCI 12/4885PIK3CA 294/4885LIMK1 1270/4885 |
| US-20190106433-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKX, PRKCQ, PRKACA | PRKCI 16/4885PIK3CA 248/4885LIMK1 1387/4885 |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKX, PRKCQ, PRKACA | PRKCI 16/4885PIK3CA 248/4885LIMK1 1387/4885 |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKDC, PRKACA | PRKCI 12/4885PIK3CA 294/4885LIMK1 1270/4885 |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKCQ, PRKDC, PRKACA | PRKCI 12/4885PIK3CA 294/4885LIMK1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.